Presentation on theme: "BESPOKE. SPECIFIC. EFFICIENT"— Presentation transcript:
1 BESPOKE. SPECIFIC. EFFICIENT Synpromics LtdRe-writing the source code for life to better harness the power of the genome for commercial applicationsDr David Venables, CEOBESPOKE. SPECIFIC. EFFICIENT
2 Investment OverviewCutting edge, IP generating, company in the emerging field of Synthetic Biology.Platform technology and IP has broad application across biotechnology; enabling more optimal commercial exploitation of The Genome Project.Multiple revenue generating opportunities through development milestone payments and attractive royalties.Low risk investment strategy, with short term revenue and long term revenue growth from rich royalty stream.Partnering agreements already in place – validated approach.Experienced Board and Management Team.
3 Synpromics BoardChairman: Dr John Brown, CBE, FRSE is the Chairman of the Cell Therapy Catapult, Mode Diagnostics Ltd and CXR Biosciences Ltd and a Non-Executive Director of Vectura Group plc. Previously, he was the Chairman of BTG plc, Axis-Shield plc, and, CEO of Acambis plc, and was a Director of Cambridge Antibody Technology plc until its acquisition by AstraZeneca. John also chairs the Roslin Foundation and co-chairs the Life Sciences Industry Advisory Board for the Scottish Government.CEO: David Venables, BSc, PhD has served as CEO of Anatara Therapeutics (a life sciences company he managed through private fund raising and IPO in Australia), CEO of Ark Therapeutics (until the sale of the company), and Managing Director of BioMelior Services Ltd, providing management and consultancy services to the biopharmaceutical industry and investment funds in the areas of bioprocess CMC, CMO/CRO services and business & product development strategy within the vaccine, gene therapy and cell therapy sectors. Previously at Intercell, he was responsible for building Intercell’s manufacturing capabilities in Europe and the USA. As Site Head for vaccine manufacturing operations in the UK he was responsible for the European and US licensure, pre-approval inspection and commercial supply of Ixiaro®, a Japanese Encephalitis vaccine, followed as Chief Operating Officer of Intercell USA Inc. based in the USA.Founder & CSO: Michael Roberts, BSc, PhD is the founder of Synpromics and developed the science behind the company's technology. He has extensive experience in the biotech industry and academia developing novel tools for genetic engineering. Michael graduated from the University of Glasgow with first class honours and completed his PhD at Cambridge University. Following academic roles at Royal Holloway University of London and the National Hellenic Research Foundation (as a prestigious Marie Curie Fellow), he joined Regulon Inc., as head of Research & Development and Board Member, where he remained until 2009 prior to founding Synpromics.NXD: David Lawrence is a highly experienced, dynamic business professional with a wide experience in leadership, strategy, business development, commercial/ operational management and trouble shooting. His experience over 25 years spans a variety of sectors in Lifesciences including pharmaceuticals, vaccines and biotech/medtech. David also has extensive international experience of mergers and acquisitions, fund raising and investor relations. Previous roles have included: Vice-President of Finance at GSK, Vice-President of Finance, Business Development and Strategy at Chiron Vaccines, CFO at Acambis PLC, (Board member of dual FTSE and NASDAQ listed company), CEO at Tayside Flow Technologies, a privately backed Medtech company and formerly Chairman at Acambis, a privately owned medical devices company. David is currently CEO of Sentinext Therapeutics, a vaccines company based in Malaysia.
4 Capital Structure Shareholder Number of Share % Investment to Date £ Michael L Roberts325,00039.3David Lawrence149,00018.0David Venables100,00012.1Andrei Lyne75,0009.1Others178,05021.5Investment to DateSeed Investment270,000Convertible Instruments500,000Grants725,000TOTAL1,495,000
5 Synpromics: Global leader in synthetic biology; Create synthetic promoter technology and IP to enable the controlled expression of a protein product in:a specific place,a specific environmenta specific timeresponse to a specific biological conditionPartners will adopt our IP in a wide range of biotechnology applicationsThe universality of the application, and specificity of control, means that every gene derived product can benefit from using Synpromics synthetic promoter IP.
6 Better Products - Better Processes The value of PromotersBiotechnology is based on the commercial exploitation of gene technology to create:novel therapeutic products to treat, and insome cases cure, diseasepersonalised & regenerative medicinessmarter diagnosticsThe power, and value, of novel technologies is increasingly reliant on the advancing the underlying mechanisms of gene & drug delivery.Synthetic promoters will be a key enabling & differentiating tool in the delivery of next generation therapeutic and regenerative medicines.Better Products - Better Processes
7 Better than existing promoters FeatureViralNaturalSyntheticHigh production levelsYESNOPredictable production for all proteinsConstitutive (non-stop) productionActive in multiple cell typesTemporal regulation of productionCell type - specific controlMultiple genes stably delivered in one productInducible upon biological/chemical stimuliTemperature sensitive
8 Cell & Gene Therapy and DNA Vaccine Market Opportunity The ApplicationDelivering a therapeutic gene to the patientHigher-producing vectors and cell lines, reducing manufacturing scale / cost of goods and overcoming the current limitations of scale-up.Targeting vector transgene expression to improve product safety and increase efficacy, overcoming current off-target gene expression.Improved targeting of autologous and allogeneic cell therapies in regenerative medicine and cancer treatment.The MarketGene and Cell Therapy is a rapidly emerging market with high unmet need and low barrier of entry to Synpromics IPCurrent gene therapy market opportunity for Hemophilia A est. $650 million$13 million annual revenue opportunity for Synpromics in this one indicationCurrent StatusDNA vaccine collaboration agreement in place with commercial partner.AAV collaboration agreement in place with commercial partner
9 Bio-Processing Market Opportunity The ApplicationSynthetic promoters driving increased protein yield, reducing process scale and reducing cost of goods.Increasing efficiency and yield of difficult to produce therapeutics.Improved adaptation of producer cell lines to industrial production environment.The MarketForecast biomedicine market value of $287 billion by 2020A conservative 1% market penetration of Synpromics IP represents $60 million annual revenueForecast industrial biofuels market value of $184 billion by 2021Current Status3 Funded proof of concept studies in progressTerm sheet for partner program in CHO cell line development under discussion
10 Use of Funds 2015 2016 TOTAL Operational Costs £330,000 £435,000 £765,000G&A Costs£175,000£250,000£425,000Project Costs(A) Bioprocessing£170,000-(B) Cell and Gene Therapy£130,000£430,000£560,000(C) Platform£103,050£273,050Total Program Costs£470,000£533,050£1,003,050Total Program Costs net R&D Tax Credits£329,000£373,135£702,135TOTAL TO RAISE£834,000£1,058,135£1,892,135
11 Staged Use of Funds The initial £850,000 investment allows: Completion of current projects and commercialisation of resulting promotersInitiation and completion of NGS screening approach allowing the company to develop its 3rd generation promoter technology and proprietary databasesInitiation of the lentiviral library system to improve efficiency of screeningInitiation of additional Bioprocessing projectBusiness development activities to increase and convert on new business leadsThe second £1,150,000 investment:Triggered upon completion of CHO, Ingenza, Touchlight & Synthace projectsAllows completion of Bioprocessing, NGS Screening and Lentiviral projectsAllows initiation of two additional projects in the cell and gene therapy sectorAllows initiation of four additional projects in the cell and gene therapy sectorAllows increase in business development activities, including key BD hire
12 Defining The Next Frontier Synpromics promoter IP will become the technology of choice in the biotech industry because it provides:unique and synthetic promoters;sequence and application are patentablecustom designed promoters for maximum productivity and stabilitypromoters which are controllable, and non-leaky, by time, place and environmentpromoters specific to target tissue or biological conditionpromoters ubiquitous in their application across all cell & gene derived products.
14 Key Company Milestones Patent Application for core technologyProof-of-concept in colorectal cancerPOC Project with Avanticell (co-funded Innovate UK)Commercial project initiated with Dow Agrosciences (DAS; co-funded by SE SMART)SynBio POC for creating CHO cell promoters (co-funded by Innovate UK)Scientific team increased to 3 x PhDsCommercial project with Ingenza for yeast promoters (co-funded Innovate UK);Commercial project with Touchlight Genetics (co-funded Innovate UK);POC Project with Synthace (co-funded Innovate UK)Two patent applications submitted relating to screening in plants and mammalian cellsThree new patent applications being prepared relating to super-expressing promoters, protoplast screening method and NGS screeningAdvanced stage of negotiations for projects with uniQure and LonzaLicensing out protoplast screening method to DAS resulting in the removal the DAS £250k (plus interest) charge to the companyQ1 2012: 1st seed round: £ per share post money = £1.0 millionQ3 2012: 2nd seed round: £1.666 per share post-money = £1.5 millionQ4 2014: 1st series A: £TBD per share post-money = £TBD million
15 Timing of Project Activities £850k Investment£1050k Investment20152016BD ActivitiesCHOBioprocess CollaborationIngenzaTouchlightSynthaceUndisclosed AAV CollaborationNGS ScreeningLentiviral LibrariesOccularMuscleBioProcessing New Project Q1BrainBioProcessing New Project Q3HeartPlatformCell / Gene Therapy ProjectBioprocessing ProjectCompletion of CHO, Ingenza, Touchlight & Synthace projects used as trigger for 2nd tranch of funding
16 IP Strategy Patent Submitted, 2011 - National Phase Bioinformatics proprietary selections algorithmsNGS screening methodologies and barcoded librariesLibrary Construction SOPProprietary database of cis-element interactionsMethods to screen libraries in specific cell typesProprietary plasmid/ viral screening vectorsPanels of synthetic promoters specific to target conditionPatent Submitted, National PhasePatent Application in PreparationPatent Submitted, 2014Patent Application in Preparation
17 Example Deal Terms Example Revenue Milestone Upfront payment to access our platform technology will allow the partner access to our libraries in order to select specific promoters for defined fields of use £Where appropriate milestone payments at following points:Selection of promoter50.000 £Successful phase 1 / 2 £Successful phase 3 £Regulatory filing / commercial approvalRoyalties on net income derived from product incorporating a Synpromics promoter2.5% - 5.0%* Synpromics reserves right to produce other promoters for the same field of use
Your consent to our cookies if you continue to use this website.